These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19266408)

  • 1. Adherence to HAART: processes explaining adherence behavior in acceptors and non-acceptors.
    Vervoort SC; Grypdonck MH; de Grauwe A; Hoepelman AI; Borleffs JC
    AIDS Care; 2009 Apr; 21(4):431-8. PubMed ID: 19266408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients and family care givers' experiences around highly active antiretroviral therapy (HAART).
    Sacajiu G; Raveis VH; Selwyn P
    AIDS Care; 2009 Dec; 21(12):1528-36. PubMed ID: 20024732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploration of factors influencing adherence to highly active anti-retroviral therapy (HAART) among people living with HIV/AIDS in Northern Thailand.
    Ruanjahn G; Roberts D; Monterosso L
    AIDS Care; 2010 Dec; 22(12):1555-61. PubMed ID: 20582752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptance-based behavior therapy to promote HIV medication adherence.
    Moitra E; Herbert JD; Forman EM
    AIDS Care; 2011 Dec; 23(12):1660-7. PubMed ID: 21732897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to antiretroviral therapy: a survey of factors associated with medication usage.
    Duggan JM; Locher A; Fink B; Okonta C; Chakraborty J
    AIDS Care; 2009 Sep; 21(9):1141-7. PubMed ID: 20024773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.
    Cruess DG; Minor S; Antoni MH; Millon T
    J Pers Assess; 2007 Dec; 89(3):277-90. PubMed ID: 18001228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study.
    Cooper V; Gellaitry G; Hankins M; Fisher M; Horne R
    AIDS Care; 2009 Apr; 21(4):520-8. PubMed ID: 19401867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating adherence to highly active antiretroviral therapy into children's daily lives: a qualitative study.
    Hammami N; Nöstlinger C; Hoerée T; Lefèvre P; Jonckheer T; Kolsteren P
    Pediatrics; 2004 Nov; 114(5):e591-7. PubMed ID: 15520091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-infected patients' adherence to highly active antiretroviral therapy: a phenomenological study.
    Mohammadpour A; Yekta ZP; Nikbakht Nasrabadi AR
    Nurs Health Sci; 2010 Dec; 12(4):464-9. PubMed ID: 21210925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient readiness to adhere to HAART.
    Grimes RM; Grimes DE
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(6):364-6. PubMed ID: 19952288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.
    Zorrilla CD; Santiago LE; Knubson D; Liberatore K; Estronza G; Colón O; Acevedo M
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1187-92. PubMed ID: 14983985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An examination of HIV/AIDS patients who have excellent adherence to HAART.
    Malcolm SE; Ng JJ; Rosen RK; Stone VE
    AIDS Care; 2003 Apr; 15(2):251-61. PubMed ID: 12856346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the theory of planned behavior to explore HAART adherence among HIV-positive immigrant Latinos: elicitation interview results.
    Vissman AT; Hergenrather KC; Rojas G; Langdon SE; Wilkin AM; Rhodes SD
    Patient Educ Couns; 2011 Dec; 85(3):454-60. PubMed ID: 21208772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term trends in adherence to antiretroviral therapy from start of HAART.
    Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Puradiredja DI; Johnson M; Swaden L; Phillips AN
    AIDS; 2010 May; 24(8):1153-62. PubMed ID: 20299959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs.
    Fumaz CR; Muñoz-Moreno JA; Moltó J; Ferrer MJ; López-Blázquez R; Negredo E; Paredes R; Gómez G; Clotet B
    AIDS Care; 2008 Aug; 20(7):796-805. PubMed ID: 18728987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of anger in adherence to highly active antiretroviral treatment in patients infected with HIV.
    Leombruni P; Fassino S; Lavagnino L; Orofino G; Morosini P; Picardi A
    Psychother Psychosom; 2009; 78(4):254-7. PubMed ID: 19468260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs.
    Ware NC; Wyatt MA; Tugenberg T
    Soc Sci Med; 2005 Aug; 61(3):565-76. PubMed ID: 15899316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.